Flat-dose Nivolumab (40 mg) in Combination With Doxorubicin, Vinblastine, and Dacarbazine (AVD) for Newly Diagnosed Advanced Classic Hodgkin Lymphoma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Newly-diagnosed histologically verified advanced stage (IIB-IV as per GHSG) classic Hodgkin lymphoma
• No past history of autoimmune disease
• Age \> 18 years
• Ejection fraction \> 50%
• ECOG 0-4
Locations
Other Locations
Russian Federation
P. Hertsen Moscow Oncology Research Institute (MORI) for administrative and economic work - the branch of the FSBI National Medical Research Radiological Centre (NMRRC) of the Ministry of Health of the Russian Federation
RECRUITING
Moscow
Contact Information
Primary
Mobil Akhmedov, MD, PhD
mobilakhmedov@gmail.com
79261802399
Time Frame
Start Date: 2025-04-15
Estimated Completion Date: 2032-01
Participants
Target number of participants: 54
Treatments
Experimental: Nivo40-AVD
Nivolumab 40 mg IV day 1 and 15; Doxorubicin 25 mg/m2 IV day 1 and 15; Vinblastine 6 mg/m2 IV day 1 and 15; Dacarbazine 375 mg/m2 day 1 and 15
Related Therapeutic Areas
Sponsors
Leads: National Medical Research Radiological Centre of the Ministry of Health of Russia